New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PASG’s income statement to Excel — free account
Passage Bio, Inc.
PASG- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
3.92
0.31
+8.59%
Follow PASG
Alert me
Passage Bio, Inc. (PASG) news
Headlines
- Remix to go public in reverse merger with once high-flying Passage Bio biopharmadive.com
- PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? Stocktwits
- Passage Bio and Remix Therapeutics Announce Merger Agreement GlobeNewswire
- Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? Insider Monkey
- Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says
- Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says
- Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
- Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights GlobeNewswire
- Passage Bio to Participate in Upcoming Investor Conferences GlobeNewswireInsider MonkeyInsider MonkeyInsider MonkeyProactiveMT NewswiresProactive
- Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights GlobeNewswire
- Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference GlobeNewswire
- Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference GlobeNewswire
- Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
- Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
- Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade Zacks
- Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces 1-for-20 Reverse Stock Split GlobeNewswire
- Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update GlobeNewswire
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know Zacks
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely? Simply Wall St.
- Passage Bio assumed with an Outperform at Wedbush TipRanks
- Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating MT Newswires
- Passage Bio Achieves Milestones in Gene Therapy Trials
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
- Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference GlobeNewswire